Receptor News and Research

RSS

Exploring immunity and severe disease caused by the SARS-CoV-2 Omicron variant

A new study describes the findings of a seroprevalence survey intended to establish the infection rates and the incidence of severe COVID-19 through December 15, 2021, in Gauteng, a crowded province that compresses a quarter of the country’s people into less than 2% of its area.

23 Dec 2021

Study reports that children develop sustained cross-reactive adaptive immunity against coronaviruses

A new study shows that both antibody and cellular arms of the adaptive immune response against SARS-CoV-2 are displayed strong, sustained, and cross-reactive against other coronaviruses, in young children than the immune responses in adults.

23 Dec 2021

How the SARS-CoV-2 Delta variant grew to dominate the UK epidemic

Researchers examine SARS-CoV-2 genomes in England to evaluate the effectiveness of COVID-19 policies.

22 Dec 2021

T-cell response to Omicron after an mRNA COVID vaccine booster

In a recent prospective observational study posted to the medRxiv* preprint server, researchers determined Omicron variant-associated T cell responses before and after a third dose of messenger ribonucleic acid (mRNA) vaccination against coronavirus disease (COVID-19) in anti-CD20-treated multiple sclerosis (MS) patients.

22 Dec 2021

Protein-based nanoparticle vaccines for protection against SARS-CoV-2

A recent review article discusses recent advances in protein-based nanoparticle vaccines against SARS-CoV-2.

22 Dec 2021

COVID can affect sperm quality for three months

Researchers determine whether SARS-CoV-2 could cross the blood-testis barrier and be detected in human semen after infection.

22 Dec 2021

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Researchers developed four distinct recombinant vesicular stomatitis virus (rVSV)-based bivalent vaccines against SARS-CoV-2 and influenza virus.

22 Dec 2021

Importance of booster vaccine doses for maintaining protection against the SARS-CoV-2 Omicron variant

A new study shows that although the Omicron variant exhibits significant immune escape compared to other SARS-CoV-2 variants, antibody neutralization can be largely restored with booster doses of mRNA vaccines.

22 Dec 2021

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

New study results highlight that Omicron has an increased affinity to ACE-2 receptors, therefore, has increased infectivity, viral load, and transmissibility compared to other variants of concern, including the Delta variant.

22 Dec 2021

Extended interval between second and third vaccination beneficial against SARS-CoV-2 Omicron variant

A new study proposes a multi-boost vaccine strategy with a longer duration between the second and third dose, as that would be beneficial in acquiring immunity against severely mutated SARS-CoV-2 variants.

22 Dec 2021

Scientists identify a panel of nanobodies with good neutralizing efficacy against SARS-CoV-2 variants of concern

A team of scientists from Canada has recently characterized a panel of nanobodies against the spike protein of SARS-CoV-2.

22 Dec 2021

Broad neutralization of SARS-CoV-2 spike protein by an unconventional antibody fragment

A new preprint research paper posted to the bioRxiv* server examines the nature and effects of the spike mutations and identifies a vulnerable point that could help develop broad-spectrum protection against circulating variants.

21 Dec 2021

Star-shaped cells in the brain regulate cognitive flexibility

As we live in a dynamically changing environment, it is important for our brain to not only learn new things but also to modify existing memories.

21 Dec 2021

How the SARS-CoV-2 Omicron variant spike protein is changing

The study assesses the degree to which the D614G mutation in the SARS-CoV-2 RBD allows access of spike protein trimers to LA-binding-like conformations.

21 Dec 2021

Molecular mechanism of SARS-Cov-2-induced thrombosis

Researchers demonstrate that the exposure of platelets to the SARS-CoV-2 spike protein promotes their activation and adhesion.

21 Dec 2021

Effect of T cell reactivity in COVID-19 infection and vaccination

Researchers recently developed an immunodiagnostic T cell assay to classify T cell immune responses of the subjects based on their coronavirus disease 2019 infection and vaccination history.

21 Dec 2021

Identifying a recurring pattern in broadly neutralizing antibodies that can target an epitope on SARS-CoV-2

Interesting research decrypts a recurring sequence in antibodies against severe acute respiratory syndrome 2 (SARS-CoV-2) and identifies it to be a board neutralizing antibody that targets a conserved epitope on the SARS-CoV-2 receptor-binding domain (RBD) of the spike protein.

21 Dec 2021

Receptor News and Research

Exploring immunity and severe disease caused by the SARS-CoV-2 Omicron variant

Study reports that children develop sustained cross-reactive adaptive immunity against coronaviruses

How the SARS-CoV-2 Delta variant grew to dominate the UK epidemic

T-cell response to Omicron after an mRNA COVID vaccine booster

Protein-based nanoparticle vaccines for protection against SARS-CoV-2

COVID can affect sperm quality for three months

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Importance of booster vaccine doses for maintaining protection against the SARS-CoV-2 Omicron variant

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

Extended interval between second and third vaccination beneficial against SARS-CoV-2 Omicron variant

Scientists identify a panel of nanobodies with good neutralizing efficacy against SARS-CoV-2 variants of concern

Broad neutralization of SARS-CoV-2 spike protein by an unconventional antibody fragment

Star-shaped cells in the brain regulate cognitive flexibility

How the SARS-CoV-2 Omicron variant spike protein is changing

Molecular mechanism of SARS-Cov-2-induced thrombosis

Effect of T cell reactivity in COVID-19 infection and vaccination

Identifying a recurring pattern in broadly neutralizing antibodies that can target an epitope on SARS-CoV-2

An Omicron wave predicted for England from December 2021 to April 2022

Study casts light on how to combine antibiotics and phage therapy to fight bacterial infection

QTQTN motif upstream of furin-cleavage site in SARS-CoV-2 infection and pathogenesis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News